Literature DB >> 16738360

Complicity theory: an explanation for the 'coxib problem'?

Paul Dieppe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16738360      PMCID： PMC1472720          DOI： 10.1177/014107680609900603

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  13 in total

1.  Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Authors:  Peter Jüni; Anne W S Rutjes; Paul A Dieppe
Journal:  BMJ       Date:  2002-06-01

Review 2.  Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs.

Authors:  Paul Dieppe; Christopher Bartlett; Peter Davey; Lesley Doyal; Shah Ebrahim
Journal:  BMJ       Date:  2004-07-03

3.  Lessons from the withdrawal of rofecoxib.

Authors:  Paul A Dieppe; Shah Ebrahim; Richard M Martin; Peter Jüni
Journal:  BMJ       Date:  2004-10-16

4.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

5.  Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis.

Authors:  Douglas J Watson; Thomas Rhodes; Bing Cai; Harry A Guess
Journal:  Arch Intern Med       Date:  2002-05-27

6.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

Authors:  B F McAdam; F Catella-Lawson; I A Mardini; S Kapoor; J A Lawson; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

Review 7.  Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.

Authors:  C J Hawkey; M J S Langman
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

8.  Behavioural medicine: changing our behaviour.

Authors:  Theresa Marteau; Paul Dieppe; Robbie Foy; Ann-Louise Kinmonth; Neil Schneiderman
Journal:  BMJ       Date:  2006-02-25

9.  Inconsistencies in cardiovascular data from COX-2 inhibitor trials--is it a class effect?

Authors:  Mark Weatherall; Sarah Aldington; Brent Caldwell; Richard Beasley
Journal:  J R Soc Med       Date:  2006-06       Impact factor: 18.000

Review 10.  Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.

Authors:  Brent Caldwell; Sarah Aldington; Mark Weatherall; Philippa Shirtcliffe; Richard Beasley
Journal:  J R Soc Med       Date:  2006-03       Impact factor: 18.000
View more
  2 in total

1.  Blood on our hands: seeing the evil in inappropriate comparators.

Authors:  Kamran Abbasi
Journal:  J R Soc Med       Date:  2013-01       Impact factor: 5.344

Review 2.  Oral cyclo-oxygenase 2 inhibitors versus other oral analgesics for acute soft tissue injury: systematic review and meta-analysis.

Authors:  Peter Jones; Rain Lamdin
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.